What is the price target for LYRA stock?
6 analysts have analysed LYRA and the average price target is 16.32 USD. This implies a price increase of 3196.97% is expected in the next year compared to the current price of 0.495.
LYRA THERAPEUTICS INC (LYRA) Forecast, Price Target & Analyst Ratings
NASDAQ:LYRA • US55234L2043
Current stock price
0.495 USD
-0.82 (-62.5%)
At close:
0.35 USD
-0.15 (-29.29%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LYRA THERAPEUTICS INC (LYRA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$7.28
- Revenue Estimate
- 190.74K
Price Target Details & History
Consensus Price Target and Range
Mean target
$16.32
Upside
+ 3,196.97%
From current price of $0.50 to mean target of $16.32, Based on 6 analyst forecasts
Low
$16.16
Median
$16.32
High
$16.80
Price Target Revisions
1 Month
0.00%
3 Months
-30.43%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for LYRA. The average price target is 16.32 USD. This implies a price increase of 3196.97% is expected in the next year compared to the current price of 0.495.
The average price target has been revised downward by 30.43% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
LYRA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about LYRA.
In the previous month the buy percentage consensus was at a similar level.
LYRA was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-06-10 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-03-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-15 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-07 | Jefferies | Downgrade | Buy -> Hold |
| 2024-05-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-06 | BTIG | Downgrade | Buy -> Neutral |
| 2024-05-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-25 | B of A Securities | Maintains | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-12 | B of A Securities | Maintains | Buy -> Buy |
| 2023-08-31 | HC Wainwright & Co. | Initiate | Buy |
| 2023-02-07 | BTIG | Maintains | Buy |
| 2022-05-24 | Cantor Fitzgerald | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$7.28
- Revenue Estimate
- 190.74K
- Revenue Q2Q
- -8.74%
- EPS Q2Q
- 8.97%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-4.43%
EPS (1 Month)
0.00%
EPS (3 Months)
-90.02%
Next Earnings Summary
LYRA is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -7.28 USD and the consensus revenue estimate is 190.74K USD.
The next earnings revenue estimate has been revised downward by 4.43% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.36M 368.97% | 1.558M 14.56% | 1.534M -1.54% | 752.76K -50.93% | 714K -5.15% | 11.694M 1,537.82% | 37.365M 219.52% | 65.586M 75.53% | 94.649M 44.31% | 112.16M 18.50% | 128.31M 14.40% | 144.92M 12.95% | |
| EBITDA YoY % growth | -53.92M -26.51% | -65.25M -21.01% | -60.262M 7.64% | -17.707M 70.62% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.99M -26.07% | -65.528M -19.16% | -60.733M 7.32% | -37.931M 37.55% | -50.803M -33.94% | -47.013M 7.46% | -30.839M 34.40% | -11.488M 62.75% | 11.048M 196.17% | 23.033M 108.48% | 33.406M 45.04% | 43.727M 30.90% | |
| Operating Margin | -4,043.38% | -4,205.91% | -3,959.13% | -5,038.89% | -7,115.29% | -402.03% | -82.53% | -17.52% | 11.67% | 20.54% | 26.04% | 30.17% | |
| EPS YoY % growth | -87.50 47.76% | -62.50 28.57% | -71.50 -14.40% | -26.17 63.39% | -7.16 72.64% | -6.48 9.54% | -4.09 36.85% | -1.36 66.83% | 0.38 127.82% | 0.57 51.35% | 0.77 33.93% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -7.28 8.97% | -1.39 76.88% | -1.57 71.49% | -1.66 50.81% | -1.76 75.77% | -1.89 -36.03% | -1.80 -14.29% | -1.89 -13.50% | -1.65 6.36% |
| Revenue Q2Q % growth | 190.74K -8.74% | 102K -44.26% | 102K -44.26% | 102K 308.00% | 102K -46.52% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.438M -6.88% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.06%
EPS Next 5 Year
14.65%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
95.96%
Revenue Next 5 Year
111.38%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
LYRA THERAPEUTICS INC / LYRA Forecast FAQ
Can you provide the upcoming earnings date for LYRA THERAPEUTICS INC?
LYRA THERAPEUTICS INC (LYRA) will report earnings on 2026-05-04.
What are the consensus estimates for LYRA THERAPEUTICS INC (LYRA) next earnings?
The consensus EPS estimate for the next earnings of LYRA THERAPEUTICS INC (LYRA) is -7.28 USD and the consensus revenue estimate is 190.74K USD.
What is the expected long term growth rate for LYRA stock?
The expected long term growth rate for LYRA THERAPEUTICS INC (LYRA) is 95.96%.